Gedeon Richter Plc. Releases Patient Information for Midiana® Contraceptive
Hungarian pharmaceutical company Gedeon Richter Plc. has issued patient information for Midiana®, a combined oral contraceptive. The medication contains drospirenone and ethinylestradiol.
Gedeon Richter Plc., a pharmaceutical company based in Hungary, has provided detailed patient information regarding its contraceptive product, Midiana®. This medication is a combined oral contraceptive pill containing two types of female sex hormones: a progestogen, drospirenone, and an estrogen, ethinylestradiol.
The primary indication for Midiana® is the prevention of pregnancy. The contraceptive effect is achieved through a combination of mechanisms, including the suppression of ovulation, an increase in the viscosity of cervical mucus, and alterations in the endometrium. The manufacturer states that when used correctly, the Pearl Index, a measure of contraceptive efficacy, is less than 1, indicating it is one of the most reliable methods of contraception.
However, the product information also highlights potential risks associated with combined hormonal contraceptives. These include an increased risk of blood clots in veins and arteries, particularly during the first year of use or when restarting the medication after a break. Patients are advised to seek medical attention if they experience symptoms suggestive of a blood clot.
The instructions also detail a comprehensive list of contraindications and precautions for using Midiana®. These encompass conditions such as a history of blood clots, heart attack, or stroke; certain inherited or acquired thrombophilia disorders; high blood pressure; severe diabetes with vascular complications; smoking over the age of 35; specific liver or heart conditions; and a history of migraines with aura. Individuals considering the use of Midiana® are strongly advised to consult with a healthcare provider to discuss potential risks and alternative contraceptive options.